Long-Term Outcome of Merkel Cell Carcinoma After Avelumab Exposure

From General Health Guidance to Targeted Risk Assessment

In the domain of mass production, the legacy of general health and science information has long emphasized broad preventive measures and public awareness. This foundation has guided populations toward understanding risk factors associated with lifestyle and environmental exposures, fostering a baseline of health literacy that supports informed decision-making. Within this context, the focus has traditionally been on common health outcomes and widely recognized hazards, such as those linked to smoking or diet. As industrial processes evolve, however, attention naturally shifts toward more specific occupational exposures that may arise in manufacturing settings. The transition from general health guidance to targeted risk assessment becomes particularly relevant when considering the potential long-term consequences of exposure to certain substances encountered during production. For instance, workers in facilities handling biological or chemical agents may face elevated risks for rare but serious conditions, including certain cancers. This pivot requires a careful examination of how legacy health principles—such as monitoring, early detection, and risk communication—can be adapted to address emerging concerns in occupational environments. The focus here is on the exposure itself, not on mechanistic pathways, but on the practical implications for surveillance and prognosis in populations with defined industrial contact.

Avelumab as a Therapeutic Agent for Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Epidemiology and Risk Factors for Merkel Cell Carcinoma

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Treatment Outcomes and Salvage Therapy in Avelumab-Refractory Patients

In a retrospective study conducted at three academic sites in Germany, five patients with metastatic MCC refractory to avelumab were subsequently treated with combined ipilimumab and nivolumab. Three out of five patients responded to this combination therapy according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study from the prospective skin cancer registry ADOREG similarly reported that ipilimumab plus nivolumab can be effective in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). A separate retrospective study confirmed that immune checkpoint inhibitors offer durable responses and significant clinical benefit, with avelumab and pembrolizumab currently approved by the U.S. Food and Drug Administration for advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Adverse Effects and Management of Immune-Related Events

Regarding adverse effects, checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab. The hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that irAEs can occur during treatment but may be manageable without discontinuing therapy.

Prognosis and Long-Term Outcomes After Avelumab Exposure

The adequacy of warnings regarding avelumab and MCC is supported by the drug's approval based on clinical trial data showing efficacy in a significant proportion of patients. However, the risk of progression remains substantial, with about half of patients not responding to initial immune checkpoint inhibitor therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Prognosis for affected patients depends on response to treatment; those who respond to avelumab may experience durable benefit, while non-responders face limited options. The timeline between avelumab exposure and documented harm is variable. Immune-related adverse events can occur during treatment, as seen in the sarcoidosis case, while progression of MCC may occur during or after therapy. For avelumab-refractory patients, subsequent treatment with ipilimumab plus nivolumab may offer a salvage option, but data are limited to small retrospective series (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In summary, avelumab represents a key therapeutic advance for metastatic MCC, with a favorable benefit-risk profile in many patients. However, the risk of non-response or progression, as well as immune-related adverse events, must be considered. Ongoing research into combination therapies and salvage regimens is needed to improve outcomes for patients who do not respond to avelumab.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is avelumab and how does it work for Merkel cell carcinoma?

What are the long-term outcomes for patients with Merkel cell carcinoma treated with avelumab?

Long-term outcomes vary. Approximately one-third of patients with chemotherapy-refractory metastatic MCC achieve objective responses with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, about 50% of patients progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For those who respond, durable benefit is possible, but non-responders have limited options. Salvage therapy with ipilimumab plus nivolumab may be effective in some avelumab-refractory patients (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

What are the common side effects of avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These may include conditions like hypercalcemia from sarcoidosis reactivation, which can be managed with corticosteroids without necessarily discontinuing therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.